Skip to main content

Table 3 Trends in hazard ratios for breast cancer mortality associated with hormone receptor status and different demographic and clinical characteristics

From: Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients

  ER+/PR+ ER+/PR- ER-/PR+ ER-/PR-
Characteristics HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Age at diagnosis, per 5 yearsa 1.05 1.04–1.06 1.07 1.04–1.09 1.07 1.03–1.10 1.06 1.05–1.07
Diagnosis year, per yearb 0.93 0.92–0.94 0.92 0.90–0.94 0.95 0.91–0.98 0.96 0.95–0.97
Tumor stagec 2.33 2.20–2.46 2.29 2.09–2.51 2.55 2.19–2.96 2.06 1.94–2.18
Tumor size (cm)d 1.27 1.24–1.30 1.29 1.24–1.34 1.33 1.25–1.41 1.22 1.20–1.25
Axillary lymph node statuse 1.71 1.65–1.78 1.55 1.46–1.66 1.61 1.44–1.80 1.64 1.58–1.70
Tumor gradef 1.62 1.55–1.70 1.49 1.36–1.63 1.72 1.46–2.03 1.24 1.16–1.32
  1. aFive-year categories. Reference = 30 to <35 years. HRs adjusted for year at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). bReference = 1990. HRs adjusted for age at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). cReference = stage 1. HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, lymph node status, and surgical and radiation treatment. Stage unknown, n = 4,728. dCategories = 0 to <1, 1 to <2, 2 to <3, 3 to <4, 4 to <5, 5 to <10, ≥10 cm. Reference = 0 to <1 cm. HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, lymph node status, and surgical and radiation treatment. Size unknown, n = 7,196. eCategories = 0, 1 to 3, 4 to 10, ≥11. Reference = 0. HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, stage, grade, and surgical and radiation treatment. Nodal status unknown, n = 22,394. fReference = grade 1. HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, stage, lymph node status, and surgical and radiation treatment. Grade unknown, n = 24,544. CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; PR, progesterone receptor; SEER, Surveillance, Epidemiology, and End Results.